Laertis Ikonomou, PhD
Co-Chair (August 2019-June 2020)

Boston University
Boston, MA, United States

[1] Ikonomou L, Wagner DE, Turner L, Weiss DJ. Translating Basic Research into Safe and Effective Cell-based Treatments for Respiratory Diseases. Ann Am Thorac Soc 2019;16:657-668. https://www.atsjournals.org/doi/10.1513/AnnalsATS.201812-890CME

[2] Weiss DJ, Turner L, Levine AD, Ikonomou L. Medical societies, patient education initiatives, public debate and marketing of unproven stem cell interventions. Cytotherapy 2018;20:165-168. https://www.sciencedirect.com/science/article/pii/S1465324917307144

[3] Wagner DE, Turner L, Panoskaltsis-Mortari A, Weiss DJ, Ikonomou L. Co-opting of ClinicalTrials.gov by patient-funded studies. Lancet Resp Med 2018;6:579-581. https://www.sciencedirect.com/science/article/abs/pii/S221326001830242X

[4] Ikonomou L, Panoskaltsis-Mortari A, Wagner DE, Freishtat R, Weiss DJ. Unproven Stem Cell Treatments for Lung Disease-An Emerging Public Health Problem. Am J Respir Crit Care Med 2017;195:P13-P14. https://www.atsjournals.org/doi/10.1164/rccm.1957P13

[5] Ikonomou L, Freishtat RJ, Wagner DE, Panoskaltsis-Mortari A, Weiss DJ. The Global Emergence of Unregulated Stem Cell Treatments for Respiratory Diseases Professional Societies Need to Act. Ann Am Thorac Soc 2016;13:1205-1207. https://www.atsjournals.org/doi/10.1513/AnnalsATS.201604-277ED